Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 431 participants.

Also called NCT03284255

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 431 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03284255
Other papers using this trial's data
  • A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial JACC. Cardiovascular interventions, 2025-01-13 DOI, PubMed 39814492

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03284255. Randomized; no masking; primary purpose treatment. Start 2017-09-11 (actual); primary completion 2020-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
Condition
Antineoplastic Agents
Intervention (Device)
study group
Intervention (Device)
control group
Lead sponsor
Shanghai Bio-heart Biological Technology Co., Ltd. (class: industry)
Collaborator
CCRF Inc., Beijing, China (class: industry)

Record details

Record id
cardio:ct-nct03284255
Content hash
fa569cdb0775b0388507abd0027d70d202b1179e94b06079bd6b4b9034af260a